What´s new at Flavine? We´ll keep you updated on any development and news on this page. Feel free to share also our event informations!
New Flavine Proprietary API
Flavine is embarking upon a new pipeline of proprietary master files of generic APIs for all markets. We are proud to announce the availability of Ruxolitinib Phosphate API.
Flavine has partnered with a reputed CDMO to develop and manufacture Ruxolitinib Phosphate. Flavine can support your filing strategy by utilizing our expertise of serving the generic industry for 45+ years.
Ruxolitinib Phosphate is a potent and selective anticancer, inhibitor of Janus kinase‑1 and Janus kinase‑2. As a BCS Class I drug, it is a candidate for BCS bio-waiver in lieu of BE study.
Ruxolitinib Phosphate is indicated for these therapeutic treatments:
Contact Flavine for Ruxolitinib Phosphate samples and more information on other salts.
Disclaimer: All products which are covered under current patents are available only for use reasonably related to the development and submission of information to the related Health Authorities to the extent permitted under applicable laws regulating the manufacture, use and sales of Active Pharmaceutical Ingredients and/or their intermediates.
New Development — Ruxolitinib Phosphate API
Approved Ruxolitinib Phosphate finished dosage forms:
New Laboratory Facility
New EU Retest & Release Laboratory
In a world where the healthcare revolution is increasingly transforming our lives, Flavine is leading the expansion of sourcing activities for its customers. For more than 45 years, we are thriving to add value to the business of both suppliers and customers by locating and developing quality manufacturers and opening up new markets.
Flavine is excited to announce our new, state of the art, GMP-compliant laboratory facility that offers comprehensive analytical services, QC retest, and release testing of active pharmaceutical ingredients and finished dosage forms. Complementing our full-service QC testing, we also provide robust method development, validation, and transfer of pharmaceutical products and raw materials.